Journal of Digestive Cancer Research 2018; 6(1): 16-24
Published online June 30, 2018
© Korean Society of Gastrointestinal Cancer
Gastric cancer is not a single, uniform disease, but rather heterogeneous in nature. It is generally not possible to cure patients with inoperable advanced or metastatic stomach cancer. In the absence of chemotherapy, the median survival time is 3 to 6 months. Therefore, several studies have confirmed the superiority of chemotherapy to the best supportive treatment, in terms of improving the quality of life and prolonging life. Various chemotherapies have been used in the past to treat advanced gastric cancer. Recently, various target therapies and immunotherapy have been introduced. However, compared to other malignancies, the quality of life and life expectancy remain relatively poor in patients with gastric cancer. We expect to overcome these difficulties in the future, with better elucidation of the molecular biology of gastric cancer.
KeywordsStomach cancer Chemotherapy Target therapy Immunotherapy
Journal of Digestive Cancer Research 2018; 6(1): 16-24
Published online June 30, 2018
Copyright © Korean Society of Gastrointestinal Cancer Research.
문희석, 정현용
충남대학교 의과대학 내과학교실, 소화기내과
Hee Seok Moon, Hyun Yong Jeong
Division of Gastroenterology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea
Gastric cancer is not a single, uniform disease, but rather heterogeneous in nature. It is generally not possible to cure patients with inoperable advanced or metastatic stomach cancer. In the absence of chemotherapy, the median survival time is 3 to 6 months. Therefore, several studies have confirmed the superiority of chemotherapy to the best supportive treatment, in terms of improving the quality of life and prolonging life. Various chemotherapies have been used in the past to treat advanced gastric cancer. Recently, various target therapies and immunotherapy have been introduced. However, compared to other malignancies, the quality of life and life expectancy remain relatively poor in patients with gastric cancer. We expect to overcome these difficulties in the future, with better elucidation of the molecular biology of gastric cancer.
Keywords: Stomach cancer, Chemotherapy, Target therapy, Immunotherapy